Monique van der Kooij

12PUBLICATIONS
38CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 06, 2025
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Els M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij

|Dec 23, 2022
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.

Monique K van der Kooij, Arjen Joosse, Karijn P M Suijkerbuijk

|Nov 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.

Daan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage

|Sep 28, 2021
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study.

Monique K van der Kooij, Olaf M Dekkers, Maureen J B Aarts

|Sep 20, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease.

Monique K van der Kooij, Karijn P M Suijkerbuijk, Olaf M Dekkers

|Feb 15, 2021
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

Monique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts

Pageof 2

Frequent Collaborators

7 joint publications

Ellen Kapiteijn

5 joint publications

Karijn Suijkerbuijk

4 joint publications

Michel W J M Wouters

3 joint publications

Astrid Van der Veldt